



SpeedX releases Compact Respiratory Multiplex in advance of UK winter
Upfront diagnosis. Combat seasonal testing surges with ease

SYDNEY, AUSTRALIA – (Sept 1, 2023). Innovative molecular diagnostic developer, SpeedX Pty. Ltd., have further expanded their Respiratory portfolio with a focused respiratory multiplex test. **PlexPCR®** Flu/RSV/SARS-CoV-2* is ideal for upfront diagnosis of clinically relevant seasonal respiratory viruses, enabling laboratories to triage samples for rapid turnaround.

PlexPCR® Flu/RSV/SARS-CoV-2 detects Influenza, Respiratory Syncytial Virus and SARS-CoV-2 virus in a single-well multiplex qPCR test. Prompt identification of these viral infections can be important for patient management. In addition, prioritising diagnosis of these common seasonal infections with a uniform testing approach can improve laboratory efficiency and productivity during seasonal testing surges.

“Seasonal respiratory surges are known to push the limits of testing capacity for many laboratories.” explained Warwick Need, Director of Sales, SpeedX. *“Adopting **PlexPCR®** Flu/RSV/SARS-CoV-2 can ease the pressure, by funnelling all respiratory swabs into a single test and, only where needed, reflexing to an extended respiratory virus panel, like **PlexPCR®** RespiVirus.”*

Affordable and efficient, **PlexPCR®** Flu/RSV/SARS-CoV-2 can easily be applied to high testing volumes. Combining the SpeedX liquid handler, **PlexPrep®**, with open platform systems, provides a flexible workflow with scalable throughput. With this solution, laboratories can easily adapt to fluctuating testing demands.

*“Initially launching in the UK under UKCA, **PlexPCR®** Flu/RSV/SARS-CoV-2 will soon also be available across other regions.”* Dr. Lopeti Lavulo, Director of Regulatory Affairs & Quality Assurance, SpeedX.

About SpeedX Pty Ltd

Founded in 2009, SpeedX is a global company with offices in Austin, London and Sydney, and distributors across Europe. SpeedX specializes in molecular diagnostic solutions that go beyond simple detection to also offer comprehensive information on antibiotic resistance. Innovative real-time polymerase chain reaction (qPCR) technology has driven market-leading multiplex detection and priming strategies. Product portfolios focus on multiplex diagnostics for sexually transmitted infection (STI), antibiotic resistance markers, and respiratory disease. For more information on SpeedX please see: <https://plexpcr.com>

* IVD product available only in the UK, under UKCA

Contact:

Michelle Howie
Associate Director | Global Strategic Marketing
michelleh@speedx.com.au
+61 499 743 199